Zymeworks Inc. ZYME
29.07 USD -2.39 (-7.60%)
At closeNov 11, 2026, 5:25 PM EST
29.07 0.00 0.00%
After hours · Nov 11, 5:25 PM ET
28.92 Day range 31.94
18.20 52-week range 31.97
- YTD
- +10.41%
- 1 year
- +47.71%
News
benzinga.com Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44 Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $39 to $44.
benzinga.com TD Cowen Maintains Buy on Zymeworks, Raises Price Target to $39 TD Cowen analyst Yaron Werber maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $39.
benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $35 to $36.- benzinga.com HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $56 HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $55 to $56.
benzinga.com Zymeworks Raises FY2026 Sales Guidance from $278.000M-$292.000M to $337.000M-$351.000M vs $302.672M Est Zymeworks (NASDAQ:ZYME) raises FY2026 sales outlook from $278.000 million-$292.000 million to $337.000 million-$351.000 million vs $302.672 million estimate.
benzinga.com Zymeworks Q3 EPS $2.28 Beats $2.18 Estimate, Sales $256.460M Beat $228.465M Estimate Zymeworks (NASDAQ:ZYME) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $2.18 by 4.59 percent. This is a 976.92 percent increase over losses of $(0.26) per…- benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.
benzinga.com Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’sZymeworks will conduct the Phase 1a monotherapy…- benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $34.
- benzinga.com Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39 Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $38 to $39.
benzinga.com Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.- benzinga.com Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million analyst estimate.
benzinga.com Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced…
benzinga.com JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33 JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.- benzinga.com Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38 Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $37 to $38.
benzinga.com Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and…
benzinga.com MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut…- benzinga.com Citizens Reiterates Market Outperform on Zymeworks, Maintains $32 Price Target Citizens analyst Reni J. Benjamin reiterates Zymeworks (NASDAQ:ZYME) with a Market Outperform and maintains $32 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55 HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $51 to $55.
benzinga.com Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.- benzinga.com Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of…
- benzinga.com B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44 B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $40 to $44.
benzinga.com Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40 Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $37 to $40.- benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $31 to $32.
- benzinga.com HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51 HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $46 to $51.
- benzinga.com Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31 Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $28 to $31.
- benzinga.com Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37 Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $34 to $37.
benzinga.com Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.- benzinga.com Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the…
- benzinga.com Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of…
- benzinga.com Reported Sunday, Zymeworks Presents Phase 1 Data For ZW191 ADC Showing 78.6% cORR In FRα-Positive And 47.4% In FRα-Negative Platinum-Resistant Ovarian Cancer Patients At ESMO 2026 ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Zymeworks, Maintains $46 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and maintains $46 price target.
- benzinga.com Zymeworks Announces $125M Buyback Plan Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced…
- benzinga.com Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $34 Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $33 to $34.
- benzinga.com Zymeworks Q1 EPS $(0.59) Down From $(0.30) YoY, Sales $2.408M Down From $27.110M YoY Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.59) per share. This is a 96.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported $2.408…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Zymeworks, Maintains $46 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and maintains $46 price target.
- benzinga.com Zymeworks Reveals New Phase 1 Data for ZW191, A Folate Receptor Alpha-Targeting ADC At AACR Annual Meeting 2026; ZW191 Demonstrates Anti-Tumor Activity In Heavily Pretreated Ovarian And Endometrial Cancers, Regardless Of FRα Expression; Confirmed Objective Response Rate Of 61% At Doses 6.4-9.6 Mg/kg In Platinum Resistant Ovarian Cancer Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced…
benzinga.com Zymeworks Presents Data On Six Poster Presentations Regarding New Preclinical Data From Its Antibody-Drug Conjugate, Payload Development Programs At American Association For Cancer Research Annual Meeting 2026 Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced…- benzinga.com The FDA Grants Fast Track Designation To Zymeworks' ZW191 For Advanced Or Metastatic Platinum-Resistant Ovarian Cancer ZW191 is an ADC engineered to target FRα, a protein expressed in several tumor types, including approximately 75% of high-grade serous ovarian carcinomas1, over 50% of endometrial cancers,2,3 and…
- benzinga.com Zymeworks Announces Jazz Pharmaceuticals To Present Four Abstracts Featuring Data From Clinical Studies Evaluating Ziihera At American Association for Cancer Research Annual Meeting Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today…
- benzinga.com Evercore ISI Group Maintains Outperform on Zymeworks, Raises Price Target to $48 Evercore ISI Group analyst Jonathan Miller maintains Zymeworks (NASDAQ:ZYME) with a Outperform and raises the price target from $33 to $48.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading…
benzinga.com Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.- benzinga.com HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $46 HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $46.
benzinga.com Forecasting The Future: 4 Analyst Projections For Zymeworks - benzinga.com Stifel Maintains Buy on Zymeworks, Raises Price Target to $47 Stifel analyst Stephen Willey maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $40 to $47.
- benzinga.com Leerink Partners Maintains Outperform on Zymeworks, Raises Price Target to $58 Leerink Partners analyst Andrew Berens maintains Zymeworks (NASDAQ:ZYME) with a Outperform and raises the price target from $52 to $58.
benzinga.com Earnings Scheduled For March 2, 2026 - benzinga.com Zymeworks And Royalty Pharma Enter Into $250M Funding From Royalty-backed Note With Repayments Due From 30% Of Worldwide Tiered Royalties On Ziihera (Zanidatamab-hrii) Owed To Zymeworks From Jazz Pharmaceuticals And BeOne Medicines Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain…